{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:06:11Z","timestamp":1789185971714,"version":"build-2803163510"},"reference-count":39,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.3892\/or.2017.5606","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T07:16:43Z","timestamp":1493277403000},"page":"3329-3340","source":"Crossref","is-referenced-by-count":8,"title":["A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer"],"prefix":"10.3892","volume":"37","author":[{"given":"Hai-Ying","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Sai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"key20180107225207_b1-or-37-06-3329","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728210902976842","article-title":"Emerging drugs for esophageal cancer","volume":"14","author":"Homs","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20180107225207_b2-or-37-06-3329","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/ng.648","article-title":"Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54","volume":"42","author":"Wang","year":"2010","journal-title":"Nat Genet"},{"key":"key20180107225207_b3-or-37-06-3329","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"key":"key20180107225207_b4-or-37-06-3329","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.med.55.091902.104433","article-title":"The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors","volume":"55","author":"Rowinsky","year":"2004","journal-title":"Annu Rev Med"},{"key":"key20180107225207_b5-or-37-06-3329","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107225207_b6-or-37-06-3329","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/1574892811666160309121238","article-title":"Anti-EGFR therapy: Strategies in head and neck squamous cell carcinoma","volume":"11","author":"Oliveira-Silva","year":"2016","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"key20180107225207_b7-or-37-06-3329","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/modpathol.3800137","article-title":"Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: An immunohistochemical and fluorescent in situ hybridization study","volume":"17","author":"Ooi","year":"2004","journal-title":"Mod Pathol"},{"key":"key20180107225207_b8-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","article-title":"Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients","volume":"23","author":"DiGiovanna","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107225207_b9-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bjc.2011.62","article-title":"The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer","volume":"104","author":"Sheng","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107225207_b10-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1517\/13543784.2014.930126","article-title":"Investigational therapies targeting the ErbB family in oesophagogastric cancer","volume":"23","author":"Moorcraft","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180107225207_b11-or-37-06-3329","first-page":"101","article-title":"Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: A mini review","volume":"1","author":"Yin","year":"2009","journal-title":"Am J Transl Res"},{"key":"key20180107225207_b12-or-37-06-3329","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s13277-013-1131-2","article-title":"The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma","volume":"35","author":"Adachi","year":"2014","journal-title":"Tumour Biol"},{"key":"key20180107225207_b13-or-37-06-3329","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/annonc\/mdn727","article-title":"High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients","volume":"20","author":"Ludovini","year":"2009","journal-title":"Ann Oncol"},{"key":"key20180107225207_b14-or-37-06-3329","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000178164","article-title":"Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer","volume":"76","author":"Takahari","year":"2009","journal-title":"Oncology"},{"key":"key20180107225207_b15-or-37-06-3329","doi-asserted-by":"crossref","first-page":"36235","DOI":"10.18632\/oncotarget.8827","article-title":"Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"key20180107225207_b16-or-37-06-3329","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.26661","article-title":"Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma","volume":"118","author":"Valsecchi","year":"2012","journal-title":"Cancer"},{"key":"key20180107225207_b17-or-37-06-3329","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","article-title":"Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial","volume":"15","author":"Dutton","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180107225207_b18-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/annonc\/mdq604","article-title":"A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma","volume":"22","author":"Chan","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180107225207_b19-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","article-title":"Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"20","author":"Lorenzen","year":"2009","journal-title":"Ann Oncol"},{"key":"key20180107225207_b20-or-37-06-3329","first-page":"430","article-title":"A phase II trial of preoperative concurrent chemotherapy\/radiation therapy plus bevacizumab\/erlotinib in the treatment of localized esophageal cancer","volume":"10","author":"Bendell","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20180107225207_b21-or-37-06-3329","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/bjc.2015.440","article-title":"Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial","volume":"114","author":"Tebbutt","year":"2016","journal-title":"Br J Cancer"},{"key":"key20180107225207_b22-or-37-06-3329","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"key":"key20180107225207_b23-or-37-06-3329","doi-asserted-by":"crossref","first-page":"27286","DOI":"10.18632\/oncotarget.15933","article-title":"A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"key20180107225207_b24-or-37-06-3329","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/187152008783497055","article-title":"Enediyne anticancer antibiotic lidamycin: Chemistry, biology and pharmacology","volume":"8","author":"Shao","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180107225207_b25-or-37-06-3329","first-page":"5419","article-title":"Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody","volume":"46","author":"Budwit-Novotny","year":"1986","journal-title":"Cancer Res"},{"key":"key20180107225207_b26-or-37-06-3329","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-09-2699","article-title":"A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity","volume":"16","author":"Guo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107225207_b27-or-37-06-3329","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3892\/or.2015.4314","article-title":"Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells","volume":"34","author":"Okita","year":"2015","journal-title":"Oncol Rep"},{"key":"key20180107225207_b28-or-37-06-3329","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12094-015-1397-5","article-title":"The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer","volume":"18","author":"Wang","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"key20180107225207_b29-or-37-06-3329","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107225207_b30-or-37-06-3329","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107225207_b31-or-37-06-3329","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107225207_b32-or-37-06-3329","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","article-title":"A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515","volume":"120","author":"Stopeck","year":"2012","journal-title":"Blood"},{"key":"key20180107225207_b33-or-37-06-3329","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4161\/mabs.3.3.15188","article-title":"A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity","volume":"3","author":"Dong","year":"2011","journal-title":"MAbs"},{"key":"key20180107225207_b34-or-37-06-3329","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/19420862.2016.1160989","article-title":"XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer","volume":"8","author":"Schanzer","year":"2016","journal-title":"MAbs"},{"key":"key20180107225207_b35-or-37-06-3329","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-010-0392-5","article-title":"A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature","volume":"103","author":"Tsai","year":"2011","journal-title":"J Neurooncol"},{"key":"key20180107225207_b36-or-37-06-3329","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-012-0904-6","article-title":"Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer","volume":"109","author":"Huang","year":"2012","journal-title":"J Neurooncol"},{"key":"key20180107225207_b37-or-37-06-3329","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1158\/1078-0432.CCR-09-0696","article-title":"A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma","volume":"15","author":"Oh","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107225207_b38-or-37-06-3329","first-page":"2888","article-title":"Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations","volume":"8","author":"L\u00f3pez-Ayll\u00f3n","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180107225207_b39-or-37-06-3329","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2184.2007.00455.x","article-title":"Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines","volume":"40","author":"Rusnak","year":"2007","journal-title":"Cell Prolif"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:42:02Z","timestamp":1601980922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2017.5606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,4,27]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.3892\/or.2017.5606"],"URL":"https:\/\/doi.org\/10.3892\/or.2017.5606","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}